Zai Lab (ZLAB) Projected to Post Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) is expected to post its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Zai Lab to post earnings of ($0.5262) per share and revenue of $112.5920 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Zai Lab (NASDAQ:ZLAB) last posted its earnings results on Saturday, February 14th. The company reported ($0.50) EPS for the quarter. The business had revenue of $127.60 million for the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%. On average, analysts expect Zai Lab to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zai Lab Trading Down 1.5%

Zai Lab stock traded down $0.31 during mid-day trading on Tuesday, hitting $20.91. 136,795 shares of the company’s stock were exchanged, compared to its average volume of 746,999. The stock has a market cap of $2.37 billion, a P/E ratio of -13.02 and a beta of 0.85. Zai Lab has a 1-year low of $15.96 and a 1-year high of $44.34. The stock has a 50 day moving average of $20.18 and a two-hundred day moving average of $20.29.

Wall Street Analysts Forecast Growth

ZLAB has been the topic of several analyst reports. Cantor Fitzgerald lowered their target price on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Weiss Ratings raised shares of Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. JPMorgan Chase & Co. lowered their target price on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. UBS Group initiated coverage on shares of Zai Lab in a research report on Wednesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Finally, Jefferies Financial Group raised shares of Zai Lab to a “strong-buy” rating in a research report on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Zai Lab has an average rating of “Moderate Buy” and an average price target of $50.00.

Insider Activity at Zai Lab

In related news, Director Richard Gaynor bought 1,731 shares of Zai Lab stock in a transaction that occurred on Tuesday, March 17th. The stock was acquired at an average price of $18.91 per share, for a total transaction of $32,733.21. Following the completion of the purchase, the director owned 56,630 shares in the company, valued at approximately $1,070,873.30. This represents a 3.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Ying Du sold 2,653 shares of the stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $20.45, for a total transaction of $54,253.85. Following the completion of the sale, the chief executive officer owned 1,122,626 shares of the company’s stock, valued at approximately $22,957,701.70. The trade was a 0.24% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 46,187 shares of company stock valued at $930,647. 4.96% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Zai Lab stock. Royal Bank of Canada lifted its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the period. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 at the end of the most recent quarter. 41.65% of the stock is owned by institutional investors.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.